Phase I Study to Evaluate the Tolerability, Safety and Efficacy of BMN-673 in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumor Malignancies That Have BRCA Mutations or Triple Negative Metastatic Breast Cancer

Trial Profile

Phase I Study to Evaluate the Tolerability, Safety and Efficacy of BMN-673 in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumor Malignancies That Have BRCA Mutations or Triple Negative Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Talazoparib (Primary) ; Carboplatin; Paclitaxel
  • Indications Advanced breast cancer; Cholangiocarcinoma; Ovarian cancer; Prostate cancer; Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Oct 2017 Outcomes of pharmacokinetic-toxicity model developed using data from this trial, presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017.
    • 08 Aug 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 02 May 2017 Planned End Date changed from 1 May 2017 to 1 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top